Tumor Immunotherapy (TI2)

 Saturday, May 7, 2022     10:15 AM – 12:15 PM ET     Oregon Ballroom 201

Tumor Immunotherapy (TI2)

Chairs

• Katelyn T. Byrne, Oregon Hlth. and Sci. Univ.
• Ichiko Kinjyo, Univ. of New Mexico

Speakers

• Jihae Ahn, Feinberg Sch. of Med., Northwestern Univ., Enhancing the antitumor response of CD8⁺ T cells by 4-1BB (CD137) co-stimulation with distinct inactivation of the type 2 adenosine receptors
• Mark E. Issa, Univ. of Montreal, Glycogen synthase kinase (GSK-3) synergizes with PD-1/PDL1 blockade to generate super-armed CD8 killers against tumors
• Sora Suzuki, Roswell Park Comprehensive Cancer Ctr., Complement C3 deficiency enhances anti-CD47 efficacy in murine ovarian cancer model
• Jasmine E. Trigg, Sartorius, Evaluation of checkpoint inhibitor therapies using a mixed lymphocyte reaction (MLR) assay
• Nikolaos E. Patsoukis, Beth Israel Deaconess Med. Ctr., Harvard Med. School, Treatment with exogenously added catalase promotes differentiation and function of central memory CD8⁺ T cells
• Allison Christians, Univ. of Colorado Anschutz Med. Campus, DNA-PK inhibition plus immune adjuvants promotes CD8 TIL infiltration, neoantigen presentation, and diversifies the tumor-reactive TCRβ repertoire in B16 melanoma
• Ichiko Kinjyo, Univ. of New Mexico, PARP-inhibition with IFNg in the ovarian tumor microenvironment induces immunogenic cancer cell death for sustained anti-tumor immunity